Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.40 |
| ▸ | PLK1 | P53350 | 3/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107279 | 0.78 | PLK1 (0.61) | PLK1RARB | |
| SCHEMBL20503271 | 0.78 | PLK1 (0.61) | PLK1RARB | |
| SCHEMBL10737641 | 0.78 | RXRB (0.41) | MCL1BCL2A1PLK1RXRBRXRA | |
| SCHEMBL1017790 | 0.77 | RXRB (0.44) | MCL1BCL2A1PLK1RXRBRXRA | |
| SCHEMBL6264701 | 0.75 | MCL1 (0.54) | MCL1BCL2A1ALDH1A1 | |
| SCHEMBL1017939 | 0.74 | RXRB (0.38) | MCL1BCL2A1RXRBRXRAALDH1A1 | |
| SCHEMBL1017987 | 0.73 | MCL1 (0.61) | MCL1PLK1RXRBRXRAALDH1A1 | |
| SCHEMBL20718934 | 0.70 | CYP3A4 (0.47) | MCL1RXRBRXRAALDH1A1RARB | |
| SCHEMBL13934196 | 0.69 | RXRB (0.41) | MCL1RXRBRXRAALDH1A1RARB | |
| SCHEMBL7606986 | 0.69 | MAPT (0.49) | ALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6323210-B2 | TRANSFERASE INHIBITOR | AGOURON PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2001-08-30 | — | — | US | disclosed |
| US-6207670-B1 | USE TO INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICROORGANISMS SUCH AS BACTERIA, YEAST AND FUNGI | AGOURON PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0674516-B1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMA (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5945427-A | INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICRORGANISMS SUCH AS FUNGI, BACTERIA AND YEASTS; TREATMENT FOR TUMORS, INFLAMMATION, PSORIASIS; IMMUNOSUPPRESSIVE ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5739141-A | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-14 | — | — | US | disclosed |
| US-5726312-A | Methods for preparing antiproliferative 5-substituted pyrimidone compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0674516-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | GART, GARS1, NUDT1 | MCL1 2576/4885BCL2A1 3684/4885PLK1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.